Capitolis Liquid Global Markets’s Regeneron Pharmaceuticals REGN Stock Holding History

Capitolis Liquid Global Markets’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.9M	Sell	75,000 -5,000	-6%	-$3.83M	0.37%	57
2025 Q4	$61.7M	Buy	80,000 +5,000	+7%	+$3.4M	0.37%	61
2025 Q3	$42.2M	Sell	75,000 -93,000	-55%	-$52.6M	0.34%	57
2025 Q2	$88.2M	Buy	168,000 +117,000	+229%	+$65.3M	0.65%	35
2025 Q1	$32.3M	Sell	51,000 -36,000	-41%	-$24.8M	0.29%	61
2024 Q4	$62M	Buy	87,000 +49,000	+129%	+$41.1M	0.6%	40
2024 Q3	$39.9M	Hold	38,000	–	–	0.42%	46
2024 Q2	$39.9M	Hold	38,000	–	–	0.49%	46
2024 Q1	$36.6M	Buy	+38,000	New	+$36.1M	0.59%	42

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capitolis Liquid Global Markets's REGN Position: Q1 2026 in Review

Capitolis Liquid Global Markets reduced its Regeneron Pharmaceuticals (REGN) stake by 6.3% in Q1 2026, selling an estimated $3.83M and leaving 75,000 shares worth $57.9M. The position accounts for 0.37% of the portfolio, ranked #57.

Capitolis Liquid Global Markets first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $88.2M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Capitolis Liquid Global Markets held 75,000 shares of Regeneron Pharmaceuticals worth $57.9M as of Q1 2026.
Capitolis Liquid Global Markets sold 5,000 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.83M.
Regeneron Pharmaceuticals made up 0.37% of Capitolis Liquid Global Markets's portfolio in Q1 2026, its #57 holding.
Capitolis Liquid Global Markets first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Capitolis Liquid Global Markets's Regeneron Pharmaceuticals position peaked at $88.2M in Q2 2025.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capitolis Liquid Global Markets's 13F filing for Q1 2026, filed 15 May 2026.